Back to Authors

Zhang, Lisa M.

0000-0002-4255-9609

Mayo Clinic

National Institutes of Health

Citations 2

Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer
Zhang, Yaqin , Mehta, Amit, Boufraqech, Myriem , Tian, Ze , Yu, Zhiya , Boxer, Matthew B., Kiefer, Jeffrey , Copland, John A. , Smallridge, Robert C., Li, Zhuyin, Kebebew, Electron , Zhang, Lisa M. , Davis, Sean , Wang, Jing , Shen, Min

Oncotarget | September 15, 2015 | Volume: 6 | Issue: 11 | Pages: 9073-9085

10.18632/oncotarget.3268 Get It

miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression
Boufraqech, Myriem , Nilubol, Naris , Gara, Sudheer Kumar, Sadowski, Samira M. , Mehta, Amit, Davis, Sean , Dreiling, Jennifer L., Copland, John A. , Smallridge, Robert C., Quezado, Martha , Kebebew, Electron , Zhang, Lisa M. , He, Mei

Cancer Research | December 9, 2014 | Volume: 75 | Issue: 2 | Pages: 367-377

10.1158/0008-5472.can-14-2304 Get It

Abstract Anaplastic thyroid cancer (ATC) is one of the most lethal human malignancies, but its genetic drivers remain little understood. In this study, we report losses in expression of the miRNA miR30a, which is downregulated in ATC compared with differentiated thyroid cancer and normal tissue. miR30a downregulation was associated with advanced differentiated thyroid cancer and higher mortality. Mechanistically, we found miR30a decreased cellular invasion and migration, epithelial–mesenchymal transition marker levels, lysyl oxidase (LOX) expression, and metastatic capacity. LOX was identified as a direct target of miR30a that was overexpressed in ATC and associated with advanced differentiated thyroid cancer and higher mortality rate. Consistent with its role in other cancers, we found that LOX inhibited cell proliferation, cellular invasion, and migration and metastasis in vitro and in vivo. Together, our findings establish a critical functional role for miR30a downregulation in mediating LOX upregulation and thyroid cancer progression, with implications for LOX targeting as a rational therapeutic strategy in ATC. Cancer Res; 75(2); 367–77. ©2014 AACR.